|
gptkbp:instanceOf
|
Controlled substance schedule
|
|
gptkbp:administeredBy
|
gptkb:Drug_Enforcement_Administration
|
|
gptkbp:contrastsWith
|
gptkb:Schedule_V_(US)
gptkb:Schedule_I_(US)
gptkb:Schedule_II_(US)
Schedule IV (US)
|
|
gptkbp:country
|
gptkb:United_States
|
|
gptkbp:criteria
|
Abuse may lead to moderate or low physical dependence or high psychological dependence
Currently accepted medical use in treatment in the United States
Potential for abuse less than Schedule I and II
|
|
gptkbp:enforcedBy
|
gptkb:Department_of_Justice
gptkb:Drug_Enforcement_Administration
|
|
gptkbp:example
|
gptkb:Anabolic_steroids
gptkb:Buprenorphine
gptkb:Ketamine
gptkb:Testosterone
gptkb:Tylenol_with_codeine
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
Schedule III (US)
|
|
gptkbp:legalCitation
|
gptkb:21_U.S.C._§_812(b)(3)
|
|
gptkbp:maximumRefills
|
5 times within 6 months
|
|
gptkbp:partOf
|
gptkb:Controlled_Substances_Act
|
|
gptkbp:prescriptionRequired
|
Yes
|
|
gptkbp:regulates
|
Controlled substances
|
|
gptkbp:bfsParent
|
gptkb:ketamine
gptkb:Buprenorphine
gptkb:Schedule_V_(US)
gptkb:Schedule_I_(US)
gptkb:buprenorphine
|
|
gptkbp:bfsLayer
|
6
|